Multi-disease endpoints intended to support the development of products to prevent or delay chronic diseases and age-related decline need to be developed by outside parties before FDA can start to build a regulatory framework, FDA Commissioner Robert Califf advised during a 3 May webinar sponsored by the Kitalys Institute’s “Targeting Healthy Longevity 2023.”
The main topic of the “healthy longevity” discussion was the evidence needed to support regulatory endpoints for so-called “healthspan” products that slow aging, reduce the risk of multiple diseases and/or...